Bone mineral metabolism changes in epileptic children receiving valproic acid
Journal of Paediatrics and Child Health, cilt.40, sa.8, ss.470-473, 2004 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 40 Sayı: 8
- Basım Tarihi: 2004
- Doi Numarası: 10.1111/j.1440-1754.2004.00431.x
- Dergi Adı: Journal of Paediatrics and Child Health
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.470-473
- Anahtar Kelimeler: Bone mineral density, Dual-energy X-ray absorptiometry, Osteocalcin, Valproic acid
- Trakya Üniversitesi Adresli: Evet
Özet
Objective: The aim of this study was to evaluate bone mineral density (BMD) in epileptic children receiving valproic acid (VPA) and to determine differences between osteopenic and non-osteopenic children. Methods: Thirty-three epileptic children, receiving VPA for at least 6 months, were compared with 33 healthy children for BMD. BMD was measured by dual-energy X-ray absorptiometry at lumbar vertebrae, femoral neck and greater trochanter. Serum calcium, phosphorus, alkaline phosphates, osteocalcin and VPA levels were also determined. Results: Patient's osteocalcin levels were significantly higher (P = 0.02) and femur and trochanter BMD values were significantly lower (P = 0.04 and P = 0.03, respectively). Duration of VPA therapy was significantly longer and doses of VPA were significantly higher in seven osteopenic patients compared with 26 non-osteopenic patients. Osteopenic patients (4.6 ± 2.4 years) were younger than non-osteopenic patients (7.8 ± 3.2 years) (P = 0.01). Conclusion: Long-term and high dose VPA therapy may cause osteopenia, primarily in younger epileptic children. These patients should be followed closely by BMD measurements.